IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-48007-8.html
   My bibliography  Save this article

Individualized prevention of proton pump inhibitor related adverse events by risk stratification

Author

Listed:
  • Bin Xia

    (Sun Yat-sen University
    Chinese Health RIsk MAnagement Collaboration (CHRIMAC))

  • Qiangsheng He

    (Sun Yat-sen University
    Chinese Health RIsk MAnagement Collaboration (CHRIMAC))

  • Fang Gao Smith

    (University of Birmingham
    University Hospitals Birmingham NHS Foundation Trust)

  • V. Georgios Gkoutos

    (University Hospitals Birmingham NHS Foundation Trust
    University of Birmingham
    University of Birmingham, Edgbaston)

  • Krishnarajah Nirantharakumar

    (University of Birmingham, Edgbaston
    University of Birmingham)

  • Zi Chong Kuo

    (Sun Yat-sen University)

  • Danni Wang

    (Sun Yat-sen University
    Chinese Health RIsk MAnagement Collaboration (CHRIMAC))

  • Qi Feng

    (University of Oxford)

  • Eddie C. Cheung

    (Sun Yat-sen University
    University of California)

  • Lunzhi Dai

    (Sichuan University)

  • Junjie Huang

    (The Chinese University of Hong Kong, Sha Tin)

  • Yuanyuan Yu

    (The Chinese University of Hong Kong, Sha Tin)

  • Wenbo Meng

    (The First Hospital of Lanzhou University)

  • Xiwen Qin

    (University of Western Australia
    Hong Kong Science Technology Park, Sha Tin)

  • Jinqiu Yuan

    (Sun Yat-sen University
    Chinese Health RIsk MAnagement Collaboration (CHRIMAC)
    Sun Yat-sen University)

Abstract

Proton pump inhibitors (PPIs) are commonly used for gastric acid-related disorders, but their safety profile and risk stratification for high-burden diseases need further investigation. Analyzing over 2 million participants from five prospective cohorts from the US, the UK, and China, we found that PPI use correlated with increased risk of 15 leading global diseases, such as ischemic heart disease, diabetes, respiratory infections, and chronic kidney disease. These associations showed dose-response relationships and consistency across different PPI types. PPI-related absolute risks increased with baseline risks, with approximately 82% of cases occurring in those at the upper 40% of the baseline predicted risk, and only 11.5% of cases occurring in individuals at the lower 50% of the baseline risk. While statistical association does not necessarily imply causation, its potential safety concerns suggest that personalized use of PPIs through risk stratification might guide appropriate decision-making for patients, clinicians, and the public.

Suggested Citation

  • Bin Xia & Qiangsheng He & Fang Gao Smith & V. Georgios Gkoutos & Krishnarajah Nirantharakumar & Zi Chong Kuo & Danni Wang & Qi Feng & Eddie C. Cheung & Lunzhi Dai & Junjie Huang & Yuanyuan Yu & Wenbo , 2024. "Individualized prevention of proton pump inhibitor related adverse events by risk stratification," Nature Communications, Nature, vol. 15(1), pages 1-12, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-48007-8
    DOI: 10.1038/s41467-024-48007-8
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-48007-8
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-48007-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-48007-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.